---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-25-001164"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:09:30.191146+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunic Q2 net loss $27M; vidofludimus reduces disability worsening 24% in PMS trial

## Summary
- Net loss of $27.0M ($0.20/share) for Q2 2025 vs $21.4M ($0.21/share) in Q2 2024.
- Cash and equivalents $55.3M; company states insufficient liquidity for 12 months without additional capital.
- Phase 2 CALLIPER: vidofludimus calcium reduced 24-week confirmed disability worsening 23.8% overall, 31.3% in PPMS.
- Phase 3 ENSURE enrollment completed (1,121 and 1,100 patients); top-line data expected by end of 2026.
- Two financings raised $70.1M gross in Q2 2025; R&D expenses $21.4M (+$3.0M YoY).

## SEC filing metadata
- accession: 0001193805-25-001164
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380525001164/0001193805-25-001164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380525001164/e664768_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-25-001164
- JSON: https://secwatch.observer/filing/0001193805-25-001164.json
- Plain text: https://secwatch.observer/filing/0001193805-25-001164.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.